Drug Shortage Report for TEVA-SPIRONOLACTONE
Report ID | 18025 |
Drug Identification Number | 00613223 |
Brand name | TEVA-SPIRONOLACTONE |
Common or Proper name | SPIRONOLACTONE |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | SPIRONOLACTONE |
Strength(s) | 100MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 100 |
ATC code | C03DA |
ATC description | POTASSIUM-SPARING AGENTS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2018-01-03 |
Estimated end date | 2018-01-19 |
Actual end date | 2018-02-15 |
Shortage status | Resolved |
Updated date | 2018-02-21 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2017-08-02 | English | Compare |
v2 | 2017-08-02 | French | Compare |
v3 | 2017-09-19 | English | Compare |
v4 | 2017-09-19 | French | Compare |
v5 | 2017-10-10 | English | Compare |
v6 | 2017-10-10 | French | Compare |
v7 | 2018-01-03 | English | Compare |
v8 | 2018-01-03 | French | Compare |
v9 | 2018-01-04 | English | Compare |
v10 | 2018-02-21 | English | Compare |
v11 | 2018-02-21 | French | Compare |
Showing 1 to 11 of 11